Johnson & Johnson
JNJ164.740USD
-2.520-1.51%
Close 07/31, 16:00（ET）Quotes delayed by 15 min
396.49BMarket Cap
18.18P/E TTM
More Details of Johnson & Johnson Company
Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. The Company operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolism. Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, cardiovascular, and vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eyecare professionals, and clinics.
Company Info
Ticker SymbolJNJ
Company nameJohnson & Johnson
IPO dateSep 25, 1944
Founded at1887
CEOMr. Joaquin Boix Duato
Number of employees138100
Security typeOrdinary Share
Fiscal year-endSep 25
AddressOne Johnson & Johnson Plaza
CityNEW BRUNSWICK
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code08933
Phone17325242455
Websitehttps://www.jnj.com/
Ticker SymbolJNJ
IPO dateSep 25, 1944
Founded at1887
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4047.85%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Ms. Elizabeth (Liz) Forminard
Ms. Elizabeth (Liz) Forminard
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
10.90K
+30.72%
Prof. Dr. John C. Reed, M.D., Ph.D.
Prof. Dr. John C. Reed, M.D., Ph.D.
Executive Vice President - Innovative Medicine, Research and Development
Executive Vice President - Innovative Medicine, Research and Development
10.66K
-64.23%
Mrs. Anne M. Mulcahy
Mrs. Anne M. Mulcahy
Independent Director
Independent Director
8.41K
+3.87%
Mr. Hubert Joly
Mr. Hubert Joly
Independent Director
Independent Director
5.00K
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Joaquin Boix Duato
Mr. Joaquin Boix Duato
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
276.91K
-32.09%
Ms. Jennifer L. Taubert
Ms. Jennifer L. Taubert
Executive Vice President, Worldwide Chairman, Innovative Medicine
Executive Vice President, Worldwide Chairman, Innovative Medicine
178.01K
+14.96%
Ms. Kathryn E. Wengel
Ms. Kathryn E. Wengel
Executive Vice President, Chief Technology Officer and Risk Officer
Executive Vice President, Chief Technology Officer and Risk Officer
94.62K
+14.54%
Mr. Joseph J. Wolk
Mr. Joseph J. Wolk
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
84.95K
+4047.85%
Ms. Vanessa Broadhurst
Ms. Vanessa Broadhurst
Executive Vice President - Global Corporate Affairs
Executive Vice President - Global Corporate Affairs
23.59K
+18.96%
Ms. Kristen Mulholland
Ms. Kristen Mulholland
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
14.12K
+20.79%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Oncology-DARZALEX
3.24B
14.79%
Interventional Solutions
2.10B
9.61%
Immunology-STELARA
1.63B
7.42%
Surgery-General
1.32B
6.04%
Surgery-Advanced
1.07B
4.90%
Other
12.53B
57.24%
By RegionUSD
Name
Revenue
Proportion
United States
12.30B
56.21%
Europe
5.11B
23.34%
Asia-Pacific, Africa
3.31B
15.12%
Western Hemisphere, excluding U.S.
1.17B
5.33%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Oncology-DARZALEX
3.24B
14.79%
Interventional Solutions
2.10B
9.61%
Immunology-STELARA
1.63B
7.42%
Surgery-General
1.32B
6.04%
Surgery-Advanced
1.07B
4.90%
Other
12.53B
57.24%
Shareholding Stats
Updated: Tue, May 13
Updated: Tue, May 13
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.67%
State Street Global Advisors (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.36%
Geode Capital Management, L.L.C.
2.47%
JP Morgan Asset Management
1.46%
Other
75.48%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.67%
State Street Global Advisors (US)
5.56%
BlackRock Institutional Trust Company, N.A.
5.36%
Geode Capital Management, L.L.C.
2.47%
JP Morgan Asset Management
1.46%
Other
75.48%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.92%
Investment Advisor/Hedge Fund
23.82%
Research Firm
3.09%
Pension Fund
2.21%
Bank and Trust
2.18%
Insurance Company
1.64%
Sovereign Wealth Fund
1.36%
Hedge Fund
0.57%
Foundation
0.10%
Other
26.09%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
5912
1.78B
73.98%
-417.03K
2025Q1
6002
1.80B
74.62%
+4.60M
2024Q4
5953
1.78B
74.14%
+8.28M
2024Q3
5699
1.77B
73.47%
+2.69M
2024Q2
5691
1.75B
72.75%
+9.12M
2024Q1
5685
1.73B
71.58%
-6.08M
2023Q4
5686
1.72B
71.40%
-7.80M
2023Q3
5524
1.72B
71.21%
-159.24M
2023Q2
5528
1.87B
71.81%
+6.27M
2023Q1
5490
1.85B
71.21%
-28.44M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
232.98M
9.68%
+1.17M
+0.50%
Mar 31, 2025
State Street Global Advisors (US)
133.79M
5.56%
-666.37K
-0.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
129.14M
5.37%
-857.93K
-0.66%
Mar 31, 2025
Geode Capital Management, L.L.C.
59.38M
2.47%
+1.72M
+2.98%
Mar 31, 2025
JP Morgan Asset Management
35.25M
1.47%
+11.21M
+46.62%
Mar 31, 2025
State Farm Insurance Companies
34.37M
1.43%
--
--
Mar 31, 2025
Norges Bank Investment Management (NBIM)
30.36M
1.26%
+1.26M
+4.34%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
24.07M
1%
+1.16M
+5.06%
Mar 31, 2025
Wellington Management Company, LLP
22.65M
0.94%
-1.71M
-7.02%
Mar 31, 2025
BlackRock Asset Management Ireland Limited
19.70M
0.82%
-178.45K
-0.90%
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares U.S. Pharmaceuticals ETF
22.5%
FT Vest DJIA Dogs 10 Target Income ETF
9.95%
Franklin Income Focus ETF
7.87%
First Trust NASDAQ Pharmaceuticals ETF
7.61%
Health Care Select Sector SPDR Fund
7.48%
iShares U.S. Healthcare ETF
7.17%
Proshares Ultra Health Care
7.06%
Fidelity MSCI Health Care Index ETF
6.72%
Touchstone Strategic Income ETF
6.64%
JPMorgan Healthcare Leaders ETF
6.58%
View more
iShares U.S. Pharmaceuticals ETF
Proportion22.5%
FT Vest DJIA Dogs 10 Target Income ETF
Proportion9.95%
Franklin Income Focus ETF
Proportion7.87%
First Trust NASDAQ Pharmaceuticals ETF
Proportion7.61%
Health Care Select Sector SPDR Fund
Proportion7.48%
iShares U.S. Healthcare ETF
Proportion7.17%
Proshares Ultra Health Care
Proportion7.06%
Fidelity MSCI Health Care Index ETF
Proportion6.72%
Touchstone Strategic Income ETF
Proportion6.64%
JPMorgan Healthcare Leaders ETF
Proportion6.58%
Dividend
A total of
56.79B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Jan 02, 2025
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Mar 04, 2025 going ex on Feb 18, 2025
Feb 18, 2025
Mar 04, 2025
Feb 18, 2025
Oct 15, 2024
JNJ.NB Final Cash Dividend of gross USD 1.24 paid on Dec 10, 2024 going ex on Nov 26, 2024
Nov 26, 2024
Dec 10, 2024
Nov 26, 2024
Jul 17, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Sep 10, 2024 going ex on Aug 27, 2024
Aug 27, 2024
Sep 10, 2024
Aug 27, 2024
Apr 16, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.24 paid on Jun 04, 2024 going ex on May 20, 2024
May 21, 2024
Jun 04, 2024
May 20, 2024
Jan 02, 2024
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Mar 05, 2024 going ex on Feb 16, 2024
Feb 20, 2024
Mar 05, 2024
Feb 16, 2024
Oct 19, 2023
JNJ.NB Final Cash Dividend of gross USD 1.19 paid on Dec 05, 2023 going ex on Nov 20, 2023
Nov 21, 2023
Dec 05, 2023
Nov 20, 2023
Jul 20, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Sep 07, 2023 going ex on Aug 25, 2023
Aug 28, 2023
Sep 07, 2023
Aug 25, 2023
Apr 18, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.19 paid on Jun 06, 2023 going ex on May 22, 2023
May 23, 2023
Jun 06, 2023
May 22, 2023
Jan 03, 2023
JNJ.NB Interim Cash Dividend of gross USD 1.13 paid on Mar 07, 2023 going ex on Feb 17, 2023
Feb 21, 2023
Mar 07, 2023
Feb 17, 2023
Oct 18, 2022
JNJ.NB Final Cash Dividend of gross USD 1.13 paid on Dec 06, 2022 going ex on Nov 21, 2022
Nov 22, 2022
Dec 06, 2022
Nov 21, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
